Last updated 26 days ago
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
530 patients around the world
Available in Spain, Chile, Brazil, Argentina, United States
Bristol-Myers Squibb
4Research sites
530Patients around the world
This study is for people with
Lung cancer
Small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer.Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system.
- Participants have already received certain types of treatment for extensive stage small cell lung cancer.Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy.
Sites
Clínica Adventista Belgrano - CABA - Buenos Aires
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Instituto Médico Río Cuarto
Recruiting
StudyTIGOS
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06646276
